ArticleJournal of orthopaedic case reports2025
Does Multiple Intravenous Tranexamic Acid Doses in Patients Undergoing Total Knee Arthroplasty using Kinematic Alignment without Tourniquet Application show any Difference in Blood Loss, Transfusion Requirements and Hospital Stays: A Randomized Controlled Study.
Article in Journal of orthopaedic case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Impact of tranexamic acid on hidden blood loss in intertrochanteric fractures: a meta-analysis of randomized controlled trials.Frontiers in surgery · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Total knee arthroplasty (TKA) is a highly effective treatment for patients with severe knee osteoarthritis, but it often results in significant blood loss, which can lead to complications. Tranexamic acid (TXA) is widely used to reduce blood loss during surgeries, including TKA. However, its effectiveness in the context of kinematic alignment without a tourniquet has not been well-studied, particularly within the Indian population. Objective: This study aimed to evaluate the impact of multiple intravenous doses of TXA on blood loss, transfusion requirements, and hospital stays in patients undergoing TKA with kinematic alignment without a tourniquet. Materials and Methods: A randomized controlled trial was conducted with 60 patients aged 50-75 years undergoing unilateral primary TKA. Participants were randomly assigned to three groups: Group A (single dose of TXA and two doses of saline), Group B (single dose of TXA and two doses of TXA), and Group C (three doses of TXA). Blood loss, hemoglobin (Hb) levels, packed cell volume (PCV), and length of hospital stay were measured preoperatively and on post-operative days 1 and 3. Results: The results showed a significant reduction in blood loss across all groups, with Group C (multiple doses of TXA) showing the greatest reduction in Hb and PCV levels, though no significant differences were found between groups. The total blood loss and maximum Hb drop were similar between groups. No patients required blood transfusions, and there were no major complications such as deep vein thrombosis or pulmonary embolism. Length of hospital stay was not significantly different between groups. Conclusion: Multiple intravenous doses of TXA in patients undergoing TKA with kinematic alignment and without a tourniquet reduced blood loss, but the reduction was less than reported in studies involving conventional TKA with tourniquet use. Additional doses of TXA did not significantly affect blood loss, transfusion requirements, or hospital stay. Further research with larger sample sizes is needed to confirm these findings and explore optimal strategies for blood management in TKA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.